Showing 1 - 10 of 37
Following a public consultation of the draft Terms of Reference for the UK COVID-19 Inquiry, the Chair, Baroness Hallett, wrote to the Prime Minister setting out a number of proposed changes to ensure that issues of concern raised by the public are explored during the course of the Inquiry.
Inquest into the death of NHS employee Mark Woolcock from COVID-19 concludes that NHS did not breach employer duty.
Two years into the pandemic, we consider its impact on the life science sector and how the risk landscape is evolving as the industry builds on the progress it has made.
The UK Government last week published draft Terms of Reference (ToR) for the Public Inquiry into the COVID-19 pandemic. Here, we consider whether the draft ToR, given the breadth of areas covered, provide an indication as to who will be afforded Core Participant status for the purpose of the Inquiry.
To ensure safe working in relation to COVID-19, the Health and Safety Executive (HSE) has undertaken a number of spot checks on hospitals. Here, we provide an overview for healthcare providers on the process and focus of such inspections, findings on past inspections and the consequences of any deemed failings.
For many countries, steering a course to economic recovery involves focusing on vaccinations. An EU vaccine "passport" has been introduced across all member nations. In Scotland, a QR system has been launched which will be required for entry to nightclubs and many large events from 1 October 2021.
Regulatory compliance in unprecedented times: how to adapt but stay on track - a guide for the European life sciences industry
The COVID-19 pandemic has had an unprecedented impact on stakeholders in the UK and EU’s life sciences industry - from companies, to third parties, governments, regulators and insurers.
On 26 February 2021, the Home Office launched a consultation into how the Government might use legislation to improve protective security and organisational preparedness at publicly accessible locations across the UK. The consultation seeks views from anyone who might be affected by a new “Protect Duty”, from individuals to businesses and public authorities. The consultation closes on 2 July 2021.
In this Q&A, Ian Kimber, Emeritus Professor of Toxicology in the Faculty of Biology, Medicine and Health at the University of Manchester, provides an immunological perspective on current issues impacting upon the life sciences sector, ranging from recently approved cancer drugs to COVID-19 vaccines.
The vulnerabilities of the life science supply chain are at the forefront of everyone’s minds, but, behind the headlines, how is the pandemic affecting attitudes to risk?